Results 11 to 20 of about 15,930 (153)

CDK4/6 Inhibitors and Curcumin Synergistically Suppress HER2- Breast Cancer via Lethal ROS and Inhibition of Metastasis. [PDF]

Cancer Sci
Schematic illustrating that CDK4/6 inhibitors combined with curcumin induce lethal ROS accumulation by disrupting redox balance, downregulating GPX4, and depleting glutathione, leading to DNA damage and lipid peroxidation. This oxidative stress triggers tumor cell death and suppresses EMT‐driven migration.
Wang C, Zou Y, Chang C, Liu S, Ke X, Hu L, Wang D, Lu Y, Luo S, Huang S, Hu Y, Yu W, Deng A, Yue M, Jiang J.   +14 more
europepmc   +2 more sources

Tracking CDK1 Dynamics With a Novel Biosensor Mouse and Clinical Cohorts to Predict CDK4/6 Inhibitor Sensitivity in ER+ Breast Cancer [PDF]

Advanced science
Cyclin‐dependent kinase (CDK) 1 activity is a dynamic marker of treatment response in estrogen receptor positive breast cancer. Patient cohorts reveal CDK1 activity increases during progression to invasive disease, where high expression correlates with poor survival. Using a novel Cdk1 biosensor mouse alongside in vitro models, we demonstrate that CDK1
Alexandrou S, Fernandez K, Huang M, Millar E, Vennin C, Eshraghi L, Lam T, Lee V, Brooks N, Stoehr J, Mendez C, Strathdee D, Stevenson D, Herrmann D, O'Toole S, Timpson P, Nobis M, Caldon C.   +17 more
europepmc   +2 more sources

Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer

Zhongliu Fangzhi Yanjiu, 2022
As the first cyclin-dependent kinases 4 and 6 inhibitors, palbociclib significantly improved the survival of the patients with the hormone receptor-positive and human epidermal growth factor receptor-2 negative breast cancer.
ZHENG Fangchao, DU Feng, LIU Haolin, WANG Xue, YUE Jian, YUAN Peng   +5 more
doaj   +1 more source

Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study

Journal of Global Oncology, 2019
PURPOSE: The selective cyclin-dependent kinase 4/6 inhibitor palbociclib was approved in Argentina in 2015 for postmenopausal women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer (ABC)
John Waller, Debanjali Mitra, Katie Mycock, Gavin Taylor-Stokes, Gary Milligan, Lin Zhan, Shrividya Iyer   +6 more
doaj   +1 more source

Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2– advanced/metastatic breast cancer in Japan: Results from the IRIS study

Cancer Treatment and Research Communications, 2022
Background: The incidence of breast cancer is rising in Japan, particularly in postmenopausal women. The CDK 4/6 inhibitor palbociclib has demonstrated efficacy in clinical studies in patients with hormone receptor-positive (HR+), human epidermal growth ...
Katie Mycock, Lin Zhan, Kieran Hart, Gavin Taylor-Stokes, Gary Milligan, Christian Atkinson, Debanjali Mitra   +6 more
doaj   +1 more source

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer

Pharmaceutics, 2022
Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic–pharmacodynamic (PK/PD) relationships for toxicity (i.e.,
Perrine Courlet, Evelina Cardoso, Carole Bandiera, Athina Stravodimou, Jean-Philippe Zurcher, Haithem Chtioui, Isabella Locatelli, Laurent Arthur Decosterd, Léa Darnaud, Benoit Blanchet, Jérôme Alexandre, Anna Dorothea Wagner, Khalil Zaman, Marie Paule Schneider, Monia Guidi, Chantal Csajka   +15 more
doaj   +1 more source

Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population

Technology in Cancer Research & Treatment, 2022
Background: Palbociclib is the most widely used cyclin-dependent kinase 4/6 inhibitor in China, but its early application efficacy on Chinese metastatic breast cancer (MBC) patients was reported deficiently.
Yusi Zhang MS, Wenlin Chen MD, Shuanglong Chen MS, Qingmo Yang MD, Zhong Ouyang MD   +4 more
doaj   +1 more source

Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma

BMC Medicine, 2022
Background Deregulation of cell-cycle pathway is ubiquitously observed in human papillomavirus negative (HPVneg) head and neck squamous cell carcinoma (HNSCC).
Ziyue Gu, Chaoji Shi, Jiayi Li, Yong Han, Bao Sun, Wuchang Zhang, Jing Wu, Guoyu Zhou, Weimin Ye, Jiang Li, Zhiyuan Zhang, Rong Zhou   +11 more
doaj   +1 more source

Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer

Breast, 2021
Background: This study aimed to provide insights into the real-world use of palbociclib, dose reductions, and drug effectiveness in (older) patients with advanced breast cancer (BC).
R.K. Ismail, J. van Breeschoten, M.W.J.M. Wouters, M. van Dartel, S. van der Flier, A.K.L. Reyners, P. de Graeff, A.M.G. Pasmooij, A. de Boer, K.E. Broekman, D.L. Hilarius   +10 more
doaj   +1 more source

Engineering Rapid Payload Release Rate in 1,6‐Elimination Processes of Self‐Immolative Linkers

Angewandte Chemie, EarlyView.
The payload release rate of self‐immolative linkers was greatly improved through stabilization of an intermediate carbocation, thereby achieving an up to 10 000‐fold improvement in rate constant. Furthermore, lipophilicity was identified as another factor that affects the release rate. This new strategy is applicable to different payloads and different
Albert Marten Schulte, Gülbahar Bozan, Francesca Amoroso, Bart Cornelissen, Wiktor Szymanski   +4 more
wiley   +2 more sources